Reverse transcriptase is an enzyme that converts RNA into DNA, running the genetic information flow in the opposite direction from what scientists once thought possible. It was discovered simultaneously in 1970 by Howard Temin and David Baltimore, a finding so significant that a headline in Nature declared the “Central Dogma Reversed.” The enzyme is best known for its role in retroviruses like HIV, but it also plays a part in human biology and has become one of the most important tools in modern medicine and laboratory science.
How the Enzyme Works
Reverse transcriptase performs two distinct jobs. First, it acts as a DNA polymerase, reading an RNA template and building a complementary strand of DNA. Second, it functions as a nuclease (called RNase H) that chews up RNA when that RNA is paired with newly made DNA. These two activities work in tandem to convert a single-stranded RNA genome into double-stranded DNA.
The process unfolds in a precise sequence of steps. The enzyme begins by using a small piece of transfer RNA as a starting point and copies a short stretch of viral RNA into DNA. The RNase H activity then degrades the original RNA from that section, freeing the new DNA strand to jump to the other end of the genome, a move called a “strand transfer.” From there, the enzyme continues copying the full length of the RNA while simultaneously degrading it. A small RNA fragment that resists degradation serves as a primer to start building the second DNA strand. A second strand transfer event lines everything up, and the enzyme completes both strands. The final product is a double-stranded DNA molecule that is actually longer than the original RNA genome, with identical sequences at both ends called long terminal repeats.
Why It Matters for HIV
Reverse transcription is the defining feature of retroviruses. The name “retrovirus” itself comes from this backward flow of genetic information. For HIV, the process is not optional. Without converting its RNA genome into DNA, the virus cannot integrate into a host cell’s chromosomes and cannot reproduce.
After HIV enters a cell, reverse transcriptase builds the double-stranded DNA copy in the cytoplasm. This DNA is then shuttled into the nucleus as part of a larger protein complex and stitched into the host’s own chromosomes by another viral enzyme called integrase. Once embedded, the viral DNA (now called a provirus) hijacks the cell’s machinery to produce new copies of the virus. This integration step is what makes HIV so persistent: the viral instructions become a permanent part of the infected cell’s genome.
Hepatitis B Uses It Differently
HIV is not the only virus that relies on reverse transcriptase. Hepatitis B virus (HBV) also encodes its own version, though it uses the enzyme in a different way. Instead of converting RNA to DNA before entering the nucleus, HBV packages its reverse transcriptase and RNA template together inside a protein shell called a nucleocapsid, then carries out DNA synthesis within that container.
HBV’s reverse transcriptase has an unusual trick for getting started. Rather than borrowing a piece of transfer RNA as a primer, the enzyme uses itself. A specific amino acid on the protein acts as the attachment point for the first DNA building block, creating a short DNA chain physically bonded to the enzyme. This protein-primed DNA then relocates to a different position on the RNA template to continue copying the full genome. Like retroviral reverse transcriptase, HBV’s version also degrades the RNA template with its RNase H activity and then uses the minus-strand DNA as a template to build the plus strand.
A High Error Rate With Big Consequences
One of the most important features of reverse transcriptase is how sloppy it is. Unlike the DNA-copying enzymes in your own cells, reverse transcriptase lacks a proofreading function. Human DNA polymerases can detect and correct mistakes as they work, keeping their error rate extremely low, roughly one mistake per million to ten million bases copied. Reverse transcriptase makes errors 10 to 100 times more frequently.
For HIV-1, lab measurements put the error rate at roughly 1 mistake per 1,700 to 17,000 bases copied. Across retroviruses more broadly, mutation rates range from about 2 in 100,000 to 6 in a million per base per replication cycle. HIV-1 is also particularly prone to frameshift errors, where the enzyme slips and inserts or deletes a base, throwing off the entire reading frame of a gene.
This sloppiness is not just a curiosity. It is the engine of viral evolution. Every round of replication introduces new mutations, producing a swarm of slightly different viral variants within a single infected person. Some of those variants will resist antiviral drugs, evade the immune system, or both. The high mutation rate is a central reason why HIV is so difficult to treat with a single drug and why combination therapy became the standard approach.
Reverse Transcriptase in Your Own Cells
Reverse transcriptase is not exclusively a viral tool. Your cells contain their own version in the form of telomerase, an enzyme that maintains the protective caps (telomeres) at the ends of your chromosomes. Telomerase has a core component called hTERT that is, functionally, a reverse transcriptase. It reads a small RNA template carried by the enzyme’s other half (hTR) and adds short, repeated DNA sequences to chromosome tips.
Without telomerase, telomeres shorten with every cell division. Once they get too short, the cell either stops dividing or self-destructs. Telomerase is highly active in rapidly dividing cells, including those lining the lungs and gut, bone marrow cells, and fetal cells during development. In most other cell types, it is barely detectable. Cancer cells frequently reactivate telomerase to divide indefinitely, which is one reason the enzyme is a target of cancer research.
The viral legacy runs even deeper. About 8% of the human genome consists of sequences from ancient retroviruses that infected our ancestors and integrated their DNA into the germline. When you include all the fragments and derivatives of those retroviral insertions, the total accounts for roughly half of human DNA. All of that sequence got there through reverse transcription events millions of years ago.
How Drugs Target the Enzyme
Because reverse transcriptase is essential for HIV and HBV replication, it became one of the first and most important drug targets in antiviral medicine. Two classes of drugs block it in different ways.
Nucleoside reverse transcriptase inhibitors (NRTIs) were the first antiretroviral drugs approved. They mimic the normal building blocks of DNA but are missing a critical chemical group needed to attach the next building block in the chain. When reverse transcriptase incorporates one of these decoys, the growing DNA strand hits a dead end and synthesis stops. NRTIs must be activated inside the cell before they work, which is why they are technically prodrugs.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) take a different approach. Instead of pretending to be DNA building blocks, they bind to a pocket near the enzyme’s active site and physically distort its shape. This slows the enzyme’s ability to add new bases, reducing its polymerase activity overall. Because the binding pocket differs between HIV-1 and HIV-2, NNRTIs only work against HIV-1.
Current HIV treatment typically combines two NRTIs with either an NNRTI, a protease inhibitor, or an integrase inhibitor. This multi-drug strategy is necessary precisely because of the enzyme’s high error rate: using a single drug almost guarantees the virus will mutate its way around it. Reverse transcriptase inhibitors are also used to prevent HIV transmission from mother to child during pregnancy and delivery, and as post-exposure prophylaxis after a potential exposure.
The Enzyme as a Lab Tool
Outside the body, reverse transcriptase has become indispensable in molecular biology and diagnostics. Its ability to convert RNA into DNA is the foundation of a technique called RT-PCR (reverse transcription polymerase chain reaction), which became a household term during the COVID-19 pandemic. In RT-PCR, the enzyme first converts viral RNA from a patient sample into a DNA copy (called cDNA), which can then be amplified and detected.
The same principle applies to research. Scientists use reverse transcriptase to build cDNA libraries, collections of DNA copies representing all the RNA messages active in a particular cell or tissue at a given moment. This makes it possible to study gene expression, discover new genes, and sequence RNA that would otherwise be too fragile and short-lived to work with directly. The enzyme that once upended a central principle of biology turned out to be one of the most versatile tools science has ever borrowed from a virus.